immunosuppressive therapies

What Are the Challenges in Nanotechnology-Based Immunosuppressive Therapies?

Despite the promising potential, several challenges need to be addressed:
- Biocompatibility: Ensuring that nanoparticles do not elicit an immune response themselves.
- Scaling Up: Manufacturing nanoparticles consistently and cost-effectively on a large scale.
- Regulatory Approvals: Navigating complex regulatory pathways for clinical approval.
- Long-Term Effects: Understanding the long-term impact of nanoparticles in the body.

Frequently asked queries:

Partnered Content Networks

Relevant Topics